Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Detection Methods Nanoplastics Sign in to save

Characterization of nanoparticles-based vaccines for COVID-19

Nature Nanotechnology 2022 139 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 60 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.

Davide Magrì, Davide Magrì, Sabrina Gioria, Giuditta Guerrini, Sabrina Gioria, Davide Magrì, Davide Magrì, Davide Magrì, Davide Magrì, Sabrina Gioria, Sabrina Gioria, Donata Medaglini, Luigi Calzolai Davide Magrì, Sabrina Gioria, Luigi Calzolai

Summary

Researchers reviewed characterization strategies for nanoparticle-based COVID-19 vaccines, arguing that physicochemical, immunological, and toxicological assays must be combined to adequately assess nanovaccine safety and efficacy, and that rigorous characterization frameworks will be essential for navigating regulatory approval of current and future nanoparticle vaccine platforms.

Several vaccines against COVID-19 use nanoparticles to protect the antigen cargo (either proteins or nucleic acids), increase the immunogenicity and ultimately the efficacy. The characterization of these nanomedicines is challenging due to their intrinsic complexity and requires the use of multidisciplinary techniques and competencies. The accurate characterization of nanovaccines can be conceptualized as a combination of physicochemical, immunological and toxicological assays. This will help to address key challenges in the preclinical characterization, will guide the rapid development of safe and effective vaccines for current and future health crises, and will streamline the regulatory process.

Read via DOI Download PDF

Share this paper

Post Share Share Pin Email